Comparative Pharmacology
Head-to-head clinical analysis: FLAGYL I V versus METRONIDAZOLE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAGYL I V versus METRONIDAZOLE IN PLASTIC CONTAINER.
FLAGYL I.V. vs METRONIDAZOLE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, a nitroimidazole antibiotic, is reduced by bacterial nitroreductases to form reactive intermediates that disrupt bacterial DNA and inhibit nucleic acid synthesis.
After intracellular reduction, metronidazole and its metabolites interact with DNA leading to inhibition of nucleic acid synthesis and cell death. It is active against anaerobic bacteria and protozoa.
500 mg IV every 6 hours. For severe infection, 750 mg IV every 6 hours.
500 mg IV every 8 hours or 7.5 mg/kg IV every 6 hours (loading dose 15 mg/kg) for most anaerobic infections.
None Documented
None Documented
8 hours (range 6-12 hours) in adults; prolonged in hepatic impairment (up to 20 hours) and neonates.
8 hours (range 6-12 hours) in adults with normal hepatic function; prolonged to 15-30 hours in severe liver disease
Renal (60-80% unchanged), fecal (6-15% as metabolites), biliary (minor).
Renal (60-80% as unchanged drug and metabolites), fecal (6-15%), biliary (<5%)
Category C
Category A/B
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic